Clinical Trial

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Study acronym: SATROPIN
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The SATROPIN study is an international, multicenter, open-label, single-arm, phase II clinical trial to assess whether the use of prophylactic administration of atropine may prevent diarrhea in participants with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) or hormone receptor-positive/HER2-negative (HR(+)/HER2-) treated with sacituzumab govitecan.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-16.
Trial Details
NCT Number NCT07367178
Lead Sponsor MedSIR
Conditions Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer
Enrollment 30 participants
Start Date 2026-07
Primary Completion 2027-06 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-28